Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 36.785 USD -0.07% Market Closed
Market Cap: 10.1B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one EXEL stock under the Base Case scenario is 29.038 USD. Compared to the current market price of 36.785 USD, Exelixis Inc is Overvalued by 21%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EXEL Relative Value
Base Case
29.038 USD
Overvaluation 21%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.8
P/S
P/S
Price to Sales
4.8
vs History
36
vs Industry
62
Median 3Y
3.8
Median 5Y
4.3
Industry
6.9
Forward
4.5
More Details
19.9
P/E
P/E
Price to Earnings
19.9
vs History
82
vs Industry
7
Median 3Y
24.7
Median 5Y
31.1
Industry
22.4
Forward
18.1
More Details
14.8
P/OCF
P/OCF
Price to OCF
14.8
vs History
79
vs Industry
11
Median 3Y
17.1
Median 5Y
18.5
Industry
19.1
More Details
15.4
P/FCFE
P/FCFE
Price to FCFE
15.4
vs History
90
vs Industry
10
Median 3Y
18.6
Median 5Y
19.8
Industry
23.2
More Details
4.6
P/B
P/B
Price to Book Value
4.6
vs History
3
vs Industry
21
Median 3Y
2.9
Median 5Y
3
Industry
2.5
More Details
4.3
EV/S
EV/S
Enterprise Value to Sales
4.3
vs History
30
vs Industry
54
Median 3Y
3.1
Median 5Y
3.5
Industry
7.5
Forward
4
More Details
4.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.4
vs History
30
vs Industry
58
Median 3Y
3.2
Median 5Y
3.6
Industry
8.9
More Details
12.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.9
vs History
82
vs Industry
10
Median 3Y
15
Median 5Y
18.6
Industry
4
Forward
12.4
More Details
13.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.4
vs History
82
vs Industry
9
Median 3Y
15.9
Median 5Y
19.5
Industry
3.7
Forward
13.1
More Details
13.2
EV/OCF
EV/OCF
Enterprise Value to OCF
13.2
vs History
68
vs Industry
12
Median 3Y
14.4
Median 5Y
15.1
Industry
4.5
More Details
13.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13.8
vs History
73
vs Industry
9
Median 3Y
15.5
Median 5Y
16.2
Industry
3.4
More Details
5.1
EV/IC
EV/IC
Enterprise Value to IC
5.1
vs History
33
vs Industry
29
Median 3Y
3.3
Median 5Y
4.1
Industry
4.6
More Details

Multiples Across Competitors

EXEL Competitors Multiples
Exelixis Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Exelixis Inc
NASDAQ:EXEL
10.4B USD 4.8 19.9 12.9 13.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 067 711 -166 671.6 -202 392.5 -200 083
US
Abbvie Inc
NYSE:ABBV
328.5B USD 5.8 77.3 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
146.8B USD 4.4 35.8 14.9 26.4
US
Gilead Sciences Inc
NASDAQ:GILD
122B USD 4.2 254.1 10.1 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.8B USD 9.9 -204.7 22.2 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 008.9 -512.6 -558.2 -543.3
AU
CSL Ltd
ASX:CSL
116.2B AUD 4.9 27.2 16.8 21
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60B USD 4.2 13.6 8.1 9.1
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.3 -63.9 -57.7
NL
argenx SE
XBRU:ARGX
30.5B EUR 15.7 41.4 -2 340 -1 568.9
P/S Multiple
Revenue Growth P/S to Growth
US
Exelixis Inc
NASDAQ:EXEL
Average P/S: 3 188 163
4.8
10%
0.5
FR
Pharnext SCA
OTC:PNEXF
35 067 711
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.2
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 008.9
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
6%
0.7
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
15.7
39%
0.4
P/E Multiple
Earnings Growth PEG
US
Exelixis Inc
NASDAQ:EXEL
Average P/E: 67
19.9
20%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 671.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.3
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
35.8
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
254.1
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -204.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.2
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
NL
argenx SE
XBRU:ARGX
41.4
28%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Exelixis Inc
NASDAQ:EXEL
Average EV/EBITDA: 14.3
12.9
20%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 392.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
14.9
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
18%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.2 N/A N/A
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.1
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 340 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Exelixis Inc
NASDAQ:EXEL
Average EV/EBIT: 18.4
13.4
19%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 083 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
11%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.1
13%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 568.9 N/A N/A

See Also

Summary
EXEL intrinsic value, competitors valuation, and company profile.
DCF Valuation
EXEL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EXEL stock valuation using valuation multiples.
Wall Street Estimates
EXEL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EXEL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.